Want to see FR:ALNEV full AI Analyst Report?
ALNEV Stock Chart & Stats
€0.01
-€0.06(-6.03%)
At close: 4:00 PM EST
€0.01
-€0.06(-6.03%)
Day’s Range― - ―
52-Week Range€0.62 - €8,508.62
Previous CloseN/A
Volume950.00
Average Volume (3M)1.46M
Market Cap
€120.89K
Enterprise Value€3.26K
Total Cash (Recent Filing)€571.79K
Total Debt (Recent Filing)€537.20K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding159,064
10 Day Avg. Volume1,456,964
30 Day Avg. Volume1,459,251
Financial Highlights & Ratios
PEG Ratio6.69
Price to Book (P/B)180.66
Price to Sales (P/S)20138.85
P/FCF Ratio-646.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces refinancing pressure and preserves financial flexibility. This gives Neovacs more room to fund development or restructure operations without the added burden of substantial debt service.
Improving Cash-Burn RateAlthough cash flow remains negative, a slower rate of cash consumption is a constructive operational trend. Sustained improvement could extend the company’s funding runway and reduce the urgency of near-term capital requirements.
Reduced Net LossThe smaller net loss indicates some improvement from the prior year’s extreme result. If maintained alongside cost control and revenue stabilization, this could support gradual progress toward a more sustainable development model.
Bears Say
Sharp Revenue DeclineA steep revenue contraction signals weak commercial traction and limited operating scale. Continued revenue volatility would constrain funding capacity, reduce the ability to absorb fixed costs, and make long-term development financing more difficult.
Persistent UnprofitabilityRecurring negative gross and operating profitability suggests the current business model is not yet economically viable at its existing scale. Without stronger products, partnerships, or cost reductions, losses may continue eroding shareholder capital.
Dependence On External CapitalThe company is not self-funding and must eventually secure external capital unless cash generation improves materially. Repeated financing needs can dilute shareholders, limit strategic flexibility, and create funding risk for ongoing biotechnology programs.
Neovacs SA News
ALNEV FAQ
What was Neovacs SA’s price range in the past 12 months?
Neovacs SA lowest stock price was €0.62 and its highest was €8508.62 in the past 12 months.
What is Neovacs SA’s market cap?
Neovacs SA’s market cap is €120.89K.
When is Neovacs SA’s upcoming earnings report date?
Neovacs SA’s upcoming earnings report date is Oct 22, 2026 which is in 63 days.
How were Neovacs SA’s earnings last quarter?
Neovacs SA released its earnings results on Mar 30, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Neovacs SA overvalued?
According to Wall Street analysts Neovacs SA’s price is currently Overvalued.
Does Neovacs SA pay dividends?
Neovacs SA does not currently pay dividends.
What is Neovacs SA’s EPS estimate?
Neovacs SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neovacs SA have?
Neovacs SA has 159,064 shares outstanding.
What happened to Neovacs SA’s price movement after its last earnings report?
Neovacs SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.446%.
Which hedge fund is a major shareholder of Neovacs SA?
Currently, no hedge funds are holding shares in FR:ALNEV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neovacs SA
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its proprietary Kinoid technology to develop treatments, particularly for chronic autoimmune and inflammatory disorders. Its lead candidate, IFNa Kinoid, an anti-interferon alpha vaccine, is currently undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, with further preclinical investigation for diabetes. Neovacs' pipeline also includes VEGF-Kinoid, which is in preclinical development for both age-related macular degeneration and various solid tumors. Additionally, IL-4/IL-13 Kinoid is in preclinical stages for allergy treatments. The company has a significant partnership with the Sunnybrook Research Institute, focusing on the preclinical advancement of VEGF Kinoid specifically for colorectal and ovarian cancers.